Senti Biosciences to present at Synthetic Biology: Engineering, Evolution, & Design Conference.
PorAinvest
martes, 24 de junio de 2025, 8:49 am ET1 min de lectura
LU--
The SEED Conference, established in 2014, is a premier technical event for synthetic biology professionals, attracting over 5,000 attendees since its inception. The conference serves as a platform for sharing research, networking, and discussing advances in synthetic biology [2].
Senti Bio is developing next-generation cell and gene therapies using its proprietary Gene Circuit platform. The company aims to engineer Gene Circuits into medicines with enhanced precision and control, specifically targeting cancer cells while sparing healthy cells. The company's pipeline includes cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications [1].
The presentation by Timothy Lu at the SEED Conference will highlight the potential of logic-gated cells in addressing the grand challenge of tumor-specific therapies. The company's Gene Circuits have shown preclinical success in both NK and T cells, and the company is exploring their potential in other modalities and diseases outside of oncology [1].
The SEED Conference is expected to provide a valuable opportunity for Senti Bio to share its innovative work, network with industry leaders, and gain insights into the latest advancements in synthetic biology [2].
References:
[1] https://www.globenewswire.com/news-release/2025/06/24/3104254/0/en/Senti-Bio-to-Present-at-the-2025-Synthetic-Biology-Engineering-Evolution-Design-SEED-Conference.html
[2] https://www.stocktitan.net/news/SNTI/senti-bio-to-present-at-the-2025-synthetic-biology-engineering-0uosxt1f3o50.html
SNTI--
TX--
Senti Biosciences will present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference. Timothy Lu, MD, PhD, Co-Founder and CEO, will present on "Solving the Grand Challenge of Tumor-Specific Therapies with Logic-Gated Cells." The conference is being held in Houston, TX from June 23-26, 2025.
Senti Biosciences, Inc. (Nasdaq: SNTI), a clinical-stage biotechnology company, will present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference in Houston, TX, from June 23-26, 2025. The company's Co-Founder and CEO, Timothy Lu, MD, PhD, will present on "Solving the Grand Challenge of Tumor-Specific Therapies with Logic-Gated Cells" on June 24, 2025, at 1:20 PM CT [1].The SEED Conference, established in 2014, is a premier technical event for synthetic biology professionals, attracting over 5,000 attendees since its inception. The conference serves as a platform for sharing research, networking, and discussing advances in synthetic biology [2].
Senti Bio is developing next-generation cell and gene therapies using its proprietary Gene Circuit platform. The company aims to engineer Gene Circuits into medicines with enhanced precision and control, specifically targeting cancer cells while sparing healthy cells. The company's pipeline includes cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications [1].
The presentation by Timothy Lu at the SEED Conference will highlight the potential of logic-gated cells in addressing the grand challenge of tumor-specific therapies. The company's Gene Circuits have shown preclinical success in both NK and T cells, and the company is exploring their potential in other modalities and diseases outside of oncology [1].
The SEED Conference is expected to provide a valuable opportunity for Senti Bio to share its innovative work, network with industry leaders, and gain insights into the latest advancements in synthetic biology [2].
References:
[1] https://www.globenewswire.com/news-release/2025/06/24/3104254/0/en/Senti-Bio-to-Present-at-the-2025-Synthetic-Biology-Engineering-Evolution-Design-SEED-Conference.html
[2] https://www.stocktitan.net/news/SNTI/senti-bio-to-present-at-the-2025-synthetic-biology-engineering-0uosxt1f3o50.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios